Do We Keep Measuring and Measuring and Measuring Adenoma Detection Rate?
Douglas K. Rex, MD, MASGE, reviewing El Rahyel A, et al. Gastrointest Endosc 2021 Oct 20.
The adenoma detection rate (ADR), first recommended by the U.S. Multi-Society Task Force on Colorectal Cancer in 2002, is a validated predictor of colorectal cancer after colonoscopy and has become the premier quality indicator for colonoscopy.
In this single-center study of 11 endoscopists who performed at least 50 screening colonoscopies per year for 5 consecutive years, overall ADR was 42%. Over the study period, the average annual ADR of 5 of the 11 endoscopists increased significantly, ranging from 0.8% to 6.3% growth. The other 6 endoscopists had statistically stable ADRs during the study period, and none of them had a decline in ADR.
Note to readers: At the time we reviewed this paper, its publisher noted that it was not in final form and that subsequent changes might be made.
El Rahyel A, Vemulapalli KC, Lahr RE, Rex DK. Implications of stable or increasing adenoma detection rate on need for continuous measurement. Gastrointest Endosc 2021 Oct 20. (Epub ahead of print) (https://doi.org/10.1016/j.gie.2021.10.017)